natgillin/translations-raw huggingface dataset:
The peptide of claim 2, wherein the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 100, 80, or 101 is substituted with phenylalanine, tyrosine, methionine, or tryptophan. 
Peptid u skladu s patentnim zahtjevom 2, naznačen time što je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO: 194, 174, 178 ili 186 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom.
A peptide consisting of the amino acid sequence according to SEQ ID No. 6 for use in the treatment of cancer. 
HR P20182151 T1 PATENTNI ZAHTJEVI 1. = Peptid koji se sastoji od slijeda aminokiselina prema SEQ ID No. 22.
separating the suspension to form a filter cake and a supernatant; and 
re-suspendiranje drugog taloga stvorenog u koraku (e), za tvorbu suspenzije,
means (1803) for parsing the signal frame from the demodulated signal; and 
2 . tablicu mrežnih podataka (NIT) iz okvira signala
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 19, 22, 34, and 358, in which 1 or 2 amino acids are substituted, deleted, or added, wherein said peptide induces cytotoxic T lymphocytes specific to a cell expressing CDH3. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78, u kojima je jedna aminokiselina zamijenjena, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
In the context of restoring vision, in a most preferred embodiment, the mammalian cell is a photoreceptor cell; a retinal rod cell; a retinal cone cell; a retinal ganglion cell; a bipolar neuron; a ganglion cell; a pseudounipolar neuron; a multipolar neuron; a pyramidal neuron, a Purkinje cell; or a granule cell. 
Stanica iz patentnog zahtjeva 11, pri čemu je stanica sisavca a) stanica fotoreceptor, štapićasta stanica retine, čunjasta stanica retine, ganglijska stanica retine, bipolarni neuron, ganglijska stanica, pseudounipolarni neuron, multipolarni neuron, piramidalni neuron, Purkinjeova stanica, ili granulirana stanica; ili b) stanica melanoma, COS stanica; BHK stanica, HEK293 stanica, CHO stanica, stanica mijeloma, ili MDCK stanica.
Database(s) (or Patent Application) 
(96) Broj europske prijave patenta:
CB-1 antagonists have also been shown to promote cessation of smoking behavior. 
CB-1 antagonisti također su pokazali poticanje prestanka ovisnosti o pušenju.
A composition or use of claim 12, wherein the disorder is selected from the group consisting of mild to moderate dementia of the Alzheimer's type, attention deficit disorder, mild cognitive impairment and age associated memory impairment. 
Spoj, kompozicija ili upotreba prema zahtjevu 6, gdje se poremećaj bira iz skupine koju čine blaga do umjerena demencija Alzheimerovog tipa, blaga kognitivna neusaglašenost i neusaglašenost memorije uslijed starenja.
substituted or unsubstituted linear or branched alkynyl; 
iv) supstituiranog ili nesupstituiranog C2-C10 nerazgranatog ili razgranatog alkinila;
receiving an accepting appliance communication (104), said communication containing a secret keycode (109a) pertaining to said presenter and a once-off shared keycode (109b); 
(a) prijema pošiljke iz prijemne naprave (104), gdje navedena pošiljka sadrži tajni kodni ključ (1094), koji pripada navedenom prikazivaču, i jedinstveni zajednički kodni ključ (109b);
The liquefied gas treatment system according to claim 1, wherein a gas component of the BOG, which is decompressed to a gas-liquid mixed state while passing through the decompressing means (22), is joined with the BOG which is discharged from the cargo tank (1;11) and supplied to the compressor (150;13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se plinovitu komponentu u trećoj struji, dekomprimiranoj u plinsko-tekuće miješano stanje, spaja s prvom strujom otparenog plina, ispuštenog iz spremnika za teret (11).
In another embodiment, in formula (VII), R41 is selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 34, pri čemu Xy je CRa4 1 Rag 1 Rag su nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
The method according to claim 7, wherein the neuraminidase inhibitor is oseltamivir or zanamivir. 
Derivat pirazina u skladu sa zahtjevom 6 ili 7, naznačen time, da je neuraminidaza inhibitor oseltamivir ili zanamivir.
The fabric according to claim 28, wherein said fourth layer comprises a waterproof breathable membrane. 
Tkanina u skladu s patentnim zahtjevom 15, naznačena time, da navedeni četvrti sloj sadržava vodootpornu membranu propusnu za zrak.
A humanized antibody specific for the protofibrillar form of the A-B peptide, wherein said antibody comprises a heavy chain comprising SEQ ID NO:2 and a light chain comprising SEQ ID NO:22. 
teški lanac koji obuhvaća polipeptidnu sekvencu SEQ ID NO: 2 i laki lanac koji obuhvaća polipeptidnu sekvencu SEQ ID NO: 22, ili -
Use of sucrose, in a lyophilized preparation of melphalan flufenamide, or a pharmaceutically acceptable salt thereof, for decreasing the reconstitution time of the lyophilized preparation of melphalan flufenamide, or a pharmaceutically acceptable salt thereof, when reconstituted in an aqueous solvent. 
Uporaba saharoze, u liofiliziranom pripravku melfalan flufenamid hidroklorida (J1), naznačena time, da je namijenjena za smanjenje vremena rekonstitucije liofiliziranog pripravka melfalan flufenamid hidroklorida (J1), kada se rekonstituira u vodenom otapalu.
The oral formulations of the invention are selected from tablets, capsules, granules and/or microgranules. 
Oralni pripravci izuma mogu biti u obliku tableta, kapsula, granula i/ili mikrogranula.
A humanized antibody having a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO:35 and SEQ ID NO:31, respectively. 
Humanizirano anti-CD40 antitijelo koje ima varijabilan teški lanac i varijabilan laki lanac koji sadrže aminokiselinske sekvence sa SEQ ID NO:53 i SEQ ID NO:52, redom, gdje antitijelo sadrži humanu imunoglobulinski Fc regiju i gdje antitijelo je IgG1 antitijelo.
Compound according to claim 1, according to Formula V: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj Formule V: ne nF
Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”, respectively). 
Nezasićeni alkili sadržavaju najmanje jednu dvostruku ili trostruku vezu između susjednih atoma ugljika (navodi ih se kao "alkenil" odnosno "alkinil").
The composition according to any one of claims 1 to 3, wherein the solvent/drug mass ratio is between 5 and 4. 
Sastav u skladu s jednim od prethodnih zahtjeva, pri čemu je topivost lijeka u otapalu manja od 90 mg/ml.
The pharmaceutical composition for oral administration according to claim 8, wherein the hydrogel-forming polymer is one polymer or two or more polymers selected from the group consisting of polyethylene oxide, hydroxypropylmethylcellulose, carboxymethylcellulose sodium, and a carboxyvinyl polymer. 
Tableta za oralnu primjenu prema zahtjevu 10, gdje je hidrogel-formirajući polimer jedan polimer ili dva ili više polimera odabrana iz skupine koju čine polietilen oksid, hidroksipropilmetilceluloza, karboksimetilceluloza natrij i karboksivinil polimer.
contacting the water and/or sludge and/or sediment of step a) with the at least one surface-treated calcium carbonate of step b) for obtaining a composite material of surface-treated calcium carbonate and impurities, wherein the at least one surface-treated calcium carbonate comprises surface-modified calcium carbonate that has been processed with cationic polymers through an additional treatment step, and wherein the surface-modified calcium carbonate is obtained by reacting a natural calcium carbonate and/or precipitated calcium carbonate with an acid and with carbon dioxide prior to the preparation of the surface-treated calcium carbonate, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. 
dovođenje u kontakt vode i/ili mulja i/ili taloga iz koraka a) sa barem jednim površinski tretiranim kalcij karbonatom koraka b) kako bi se dobio kompozitni materijal površinski tretiranog kalcij karbonata i nečistoća, pri čemu površinski tretirani kalcij karbonat sadrži površinski modificirani kalcij karbonat koji je bio procesiran sa kationskim polimerima kroz dodatni korak obrade, pri čemu je površinski modificirani kalcij karbonat dobiven reagiranjem prirodnog kalcij karbonata i/ili istaloženog kalcij karbonata sa kiselinom i ugljik dioksidom prije priprave površinski tretiranog kalcij karbonata, pri čemu je ugljik dioksid dobiven in situ kiselinskom obradom i/ili je doveden iz vanjskog izvora.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 25, wherein the one or more further therapeutic agents are selected from the group consisting of cisplatin, gefitinib, cetuximab, rituximab, bevacizumab, erlotinib, bortezomib, thalidomide, pamidronate, zoledronic acid, clodronate, risendronate, ibandronate, etidronate, alendronate, tiludronate, arsenic trioxide, lenalidomide, filgrastim, pegfilgrastim, sargramostim, suberoylanilide hydroxamic acid, and SCIO-469. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema zahtjevu 22, naznačen time, što je jedno ili više dodatnih terapeutskih sredstava odabrano iz grupe koja sadrži cisplatin, gefitinib, cetuksimab, rituksimab, bevacizumab, erlotinib, bortezomib, talidomid, pamidronat, zolendronatnu kiselinu, klodronat, risendronat, ibandronat, etidronat, alendronat, tiludronat, arsen trioksid, lenalidomid, filgrastim, pegfilgrastim, sargramostim, suberoilanilid hidroksamsku kiselinu i SCIO-469.
Use of the antibody or antibody fragment of any one of claims 1 to 5 in research or in vitro diagnostic applications, wherein said antibody or antibody fragment comprises a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela 12 bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
The crystalline salt form of Claim 2, wherein the crystalline salt form is characterized by a differential scanning calorimetry trace recorded at a heating rate of 10°C per minute which shows a maximum in endothermic heat flow at a temperature between about 190°C and about 205°C. 
Kristalni oblik soli u skladu s patentnim zahtjevom 2, naznačen time, da je kristalni oblik soli karakteriziran bilježenjem traga diferencijalnom pretražnom kalorimetrijom pri zagrijavanju od 10°C po minuti, koji pokazuje maksimum u endotermičkom toplinskom protoku pri temperaturi od oko 190°C i oko 205°C.
The invention further relates to a process for obtaining compounds of the formula VIII, which comprises reacting a compound of the formula VI with the compound of formula VII W—CH2-A2-R15 (VII) 
Postupak dobivanja spojevi formule VIII u skladu s patentnim zahtjevima 6 ili 7, naznačen time što se sastoji u reakciji spoja formule VI s spojem formule VII W-CH,-A2-R15
The method of any one of claims 1 to 8, which comprises the first polypeptide having an antigen-binding activity and the second polypeptide having no antigen-binding activity, and wherein the first polypeptide having an antigen-binding activity comprises an amino acid sequence of an antigen-binding domain of a receptor and an amino acid sequence of an antibody Fc domain, and the second polypeptide having no antigen-binding activity comprises an amino acid sequence of an antibody Fc domain. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 i 2 i) do 2 iv), koja obuhvaća prvi polipeptid koji ima antigen-vezujuću aktivnost i drugi polipeptid koji nema antigen-vezujuću aktivnost, i pri čemu prvi polipeptid koji ima antigen-vezujuću aktivnost sadrži aminokiselinsku sekvencu antigen-vezujuće domene receptora i aminokiselinsku sekvencu Fc domene antitijela, i drugi polipeptid koji nema antigen-vezujuću aktivnost sadrži aminokiselinsku sekvencu Fc domena antitijela.
Compound of any one of claims 1 to 7 for use in the treatment, prevention or amelioration of pain, wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain, pain due to osteoarthritis, pain due to arthritis, pain due to rheumatoid arthritis, cancer pain, pain due to spinal cord injury, surgical pain, post-operative pain or acute pain. 
Spoj za uporabu prema zahtjevu 15, naznačen time da je bol odabrana iz skupine koja sadrži kroničnu bol, neuropatsku bol, upalnu bol, bol zbog osteoartritisa, bol zbog artritisa, bol zbog reumatoidnog artritisa, bol zbog karcinoma, bol zbog ozljede leđne moždine, operativnu bol, postoperativnu bol ili akutnu bol.
The present invention relates to compositions comprising one or more of a tiacumicin compound as the active ingredient in admixture with an excipient, selected from the group consisting of xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof, which is used as an anti-foaming agent. 
HR P20182110 T1 PATENTNI ZAHTJEVI nos Uporaba pomoćne tvari odabrane iz skupine koja sadrži ksantan gumu, karagenan, natrijev alginat, guar gumu, celulozu koja se može raspasti u vodi i njihove mješavine kao agens protiv pjenjenja u sastavu kojeg čimi kao aktivni sastojak jedan ili više spojeva tiakumicina, njegov stereoizomer, njegov polimorf ili njegov farmaceutski prihvatljiv solvat u vodi.
The composition of claim 1, wherein the amount of the alcohol ranges from about 1.0 to about 9.0, from about 2.0 to about 5.0 or from about 2.0 to about 4.0 molar equivalents per molar equivalent of trichloroisocyanuric acid. 
Postupak prema zahtjevu 1, naznačen time da je količina prve baze u rasponu od oko 1 do oko 10, od oko 2 do oko 7 ili od oko 3 do oko 6 molarnih ekvivalenata po molarnom ekvivalentu agensa za acililaranje.
parallel clipper 78 glue applicator for veneer 
naprava za nanošenje ljepila za furnir 79
An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-6 receptor (hIL-6R) with a KD of 500 pM or less, as measured by surface plasmon resonance, wherein the heavy chain CDRs and the light chain CDRs comprise: 
PATENTNI ZAHTJEVI Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na receptor humanoginterleukina 6 (hIL-6R) sa konstantom Kp od 500 pM ili manje, izmjereno površinskom plazmon rezonancijom, naznačen time, da:
the sequence encoding the autoactivating proelastase protein is multimerized; 
(a) sekvenca koja kodira autoaktivacijski protein proelastaze je multimerizirana;
The oral dosage form of claim 3 wherein Formula 11, Formula 22, and Formula 33 correspond to the following structures: and optionaiiy the weight ratio of the monomers of Formulae 11A:22A:33A in the polymer is 90:5:5. 
X, je alkilen, eterski dio ili amidni dio. Oralni oblik doziranja prema zahtjevu 3 naznačen time što Formula 11, Formula 22, i Formula 33 odgovaraju slijedećim strukturama:
The reaction is stirred at 80 °C for about 24 hours, filtered, and concentrated. 
Reakcijsku smjesu miješa se otprilike 24 sata na 60 "C, filtrira, te koncentrira.
Composite according to claim 1, wherein the cementitious composition is a concrete. 
Uporaba prema zahtjevu 1, pri čemu je cementna smjesa beton.
a contiguous sequence of the human λ light chain locus that spans from Vλ3-29 to Vλ3-1 and a contiguous sequence of the human λ light chain locus that spans from Vλ5-52 to Vλ1-40. 
graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ5- 52 do hVλ1-40 i graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ3-29 do hVλ3-1.
Since the plunger rod 12 is not actuated, there will be no change in pressure in chamber 21. 
Budući da spojna šipka klipa 12 nije aktivirana, ne će biti promjene tlaka u komori 21.
This product was dissolved in THF (70 mL) and cooled to 0° C. Tetrabutylammonium fluoride trihydrate (4.21 g, 13.3 mmol) dissolved in THF (40 mL) was added dropwise at 0° C. and the mixture was stirred at this temperature for 15 minutes. 
Ovaj je proizvod otopljen u THF (70 mL) i ohlađen na 0 stupnjeva C (4,21 g, 13,3 mmola) rastopljen u THF (40 mL) dodan je, kap po kap, pri O stupnjeva C i smjesa je miješana na toj temperaturi 15 minuta.
The multispecific antigen-binding molecule of claim 3, wherein the first and second polypeptides comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region, and wherein the third polypeptide and the fourth polypeptide are a commonly shared L chain. 
HR P20180421 T1 prvi i drugi polipeptid obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela, te su pritom treći polipeptid i četvrti polipeptid zajednički korišten L-lanac. 3. < Multispecifično protutijelo prema zahtjevu 2, naznačeno time, da:
9 provides a diagram showing the connection of the receiver, used in the present invention, to the anchor winch of the boat. 
Slika 9 je dijagram koji prikazuje spoj prijemnika, koji se koristi u opisanom izumu, i sidrenog vitla plovila;
Rate of animals with thrombotic occlusion (% of animals protected) Control 
Broj životinja s tromboznom okluzijom (% zaštićenih životinja) Kontrola
The compound according to any one of claims 16 to 19, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein substituent group D is carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, or heterocycle lower alkyl optionally substituted by substituent group C (wherein substituent group C is same as that of claim 1). 
Spoj prema bilo kojem od zahtjeva 16 do 19, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da supstituentska skupina D je kako slijedi: karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, ili heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom €, (gdje supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 1).
is any amino acid residue, 
X. je bilo koji aminokiselinski ostatak,
Preferably, the process according to the invention can be characterised in that in step (S3) after the lyophilisation the composite material is additionally subjected to a heat treatment at from 80 to 120° C. for from 0.25 to 48 hours. 
Postupak prema patentnom zahtjevu 27, naznačen time, da se u koraku (S3) nakon liofilizacije kompozitni materijal dodatno podvrgava toplinskoj obradi pri temperaturi od 80 do 120 *C od 0,25 do 48 sati.
A pharmaceutical combination of Claim 25 wherein the hypolipidemic agent is a cholesterol absorption inhibitor including ezetimibe. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je hipolipidemijsko sredstvo inhibitor apsorpcije kolesterola, uključujući ezetimib.
In one embodiment, R4 is hydrogen or halo. In one embodiment, R5 is halo. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R* vodik ili halo.
Method for treating water at low cost, according to any one of claims 1 to 10, wherein a dechlorination step is performed if residual chlorine is detected, the dechlorination step comprising an active carbon filter or chemicals comprising sodium bisulfite, sodium metabisulfite, or a combination thereof. 
Metoda niskih troškova za tretiranje vode, u skladu s bilo kojim od patentnih zahtjeva 1 do 10, pri čemu se korak deklorinacije provodi ako je detektiran ostatni klor, korak dekloracije obuhvaća filtar od aktivnog ugljika ili kemikalije koje obuhvaćaju natrijev bisulfit, natrijev metabisulfit, ili njihovu kombinaciju.
and wherein all aryl-, cycloalkyl-, cyclic amide, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1 R1', R1" and R5 may be unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, =O, halogen, C1-6-alkyl, phenyl, C1-6-alkyl substituted by halogen or C1-6-alkoxy; 
i gdje svaki aril-, cikloalkil-, ciklički amid, heterocikloalkil- ili heteroarilne skupine s 5 ili 6 članova kao što je definirano za R1, R1’, R1" i R5 mogu biti nesupstituirani ili supstituirani s jednim ili više supstituenata izabranih iz skupine koja se sastoji od hidroksi, =O, halogen, C1-6-alkil, fenil, C1-6-alkil supstituiran halogenom ili C1-6-alkoksi;
a liquid comestible, is produced. 
tekuća jestvina.
The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is formulated for treatment of a breast cancer. 
Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 12, gdje rak je rak dojke.
X' is a second halide anion which is different from the first halide anion; and 
X je drugi halidni anion različit od prvog halidnog aniona i zje veći od 0 a manji od 1, a poželjno je da je z od 0, 05 do 0, 95.
A combination according to claim 1 or 2, wherein the B2 agonist is a long-acting B2 agonist. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid budesonid.
A method of recovering wood fibres from engineered wood material, comprising the steps of: mixing shredded engineered wood material with water to form a slurry; and passing an electric current through the slurry to heat the shredded wood material and thereby weaken the bonding between wood fibres in the wood material. 
Postupak prikupljanja drvnih vlakana iz obrađenog drvnog materijala, naznačen time što obuhvaća slijedeće korake: miješanje isječenog obrađenog drvnog materijala s vodom kako bi se dobio mulj; i propuštanje električne struje kroz mulj kako bi se zagrijao isječeni drvni materijal, a time i oslabilo veze između drvnih vlakana u drvnom materijalu.
The compound or salt for use according to any one of claims 1 to 11, wherein said method comprises administering said compound or salt and said additional pharmaceutical agent simultaneously to the patient. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, za uporabu u postupku liječenja bolesti izabranih od kaheksije, mijeloproliferativnog poremećaja i raka kod pacijenta.
at least one light chain variable region, said light chain variable region comprising at least one member from the group consisting of: 
(ili) (a) najmanje jednu varijabilnu regiju lakog lanca, spomenuta varijabilna regija lakog lanca obuhvaća:
a biologically active fragment of any one of (i) to (v); and 
(iv) biološki aktivan fragment G protein-kupiranog receptora bilo kojeg (i) do (iii); te
Phosphatidylcholine for use in the method of claim 7, wherein said therapeutically effective amount of phosphatidylcholine ranges from about 100 mg to about 8 g per day, or wherein said therapeutically effective amount of phosphatidylcholine ranges from about 500 mg to about 4 g per day, or wherein said therapeutically effective amount of phosphatidylcholine is about 2 g per day. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 7, naznačen time, da se spomenuta terapeutski djelotvorna količina fosfatdilkolina nalazi u rasponu od oko 100 mg do oko 8 g po danu, ili time, da se terapeutski djelotvorna količina fosfatdilkolina nalazi u rasponu od oko 500 mg do oko 4 g po danu, ili time, da je terapeutski djelotvorna količina fosfatdilkolina oko 2 g po danu.